Literature DB >> 1634602

Transforming growth factor-beta in disease: the dark side of tissue repair.

W A Border1, E Ruoslahti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1634602      PMCID： PMC443055          DOI： 10.1172/JCI115821

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  75 in total

Review 1.  Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a "magic bullet".

Authors:  W R Hermans; B J Rensing; B H Strauss; P W Serruys
Journal:  Am Heart J       Date:  1991-07       Impact factor: 4.749

2.  Transforming growth factor-beta production in anti-glomerular basement membrane disease in the rabbit.

Authors:  T Coimbra; R Wiggins; J W Noh; S Merritt; S H Phan
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

3.  Mesangial cell autoantigens in immunoglobulin A nephropathy and Henoch-Schönlein purpura.

Authors:  D J O'Donoghue; A Darvill; F W Ballardie
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

4.  Dietary protein restriction rapidly reduces transforming growth factor beta 1 expression in experimental glomerulonephritis.

Authors:  S Okuda; T Nakamura; T Yamamoto; E Ruoslahti; W A Border
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

5.  Immunohistochemical localization of growth factors in fetal wound healing.

Authors:  D J Whitby; M W Ferguson
Journal:  Dev Biol       Date:  1991-09       Impact factor: 3.582

6.  Polarized regulation of fibronectin secretion and alternative splicing by transforming growth factor.

Authors:  A Wang; D S Cohen; E Palmer; D Sheppard
Journal:  J Biol Chem       Date:  1991-08-25       Impact factor: 5.157

7.  Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis.

Authors:  T J Broekelmann; A H Limper; T V Colby; J A McDonald
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

8.  Transforming growth factor-beta and suppression of humoral immune responses in HIV infection.

Authors:  J Kekow; W Wachsman; J A McCutchan; W L Gross; M Zachariah; D A Carson; M Lotz
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

9.  Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients.

Authors:  M Nobuyoshi; T Kimura; H Ohishi; H Horiuchi; H Nosaka; N Hamasaki; H Yokoi; K Kim
Journal:  J Am Coll Cardiol       Date:  1991-02       Impact factor: 24.094

10.  Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals.

Authors:  M E Brandes; J B Allen; Y Ogawa; S M Wahl
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808
View more
  200 in total

Review 1.  Autocrine and paracrine mechanisms in the early stages of diabetic nephropathy.

Authors:  G Pugliese; F Pricci; G Romeo; G Leto; L Amadio; C Iacobini; U Di Mario
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

2.  Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters.

Authors:  Q Wang; Y Wang; D M Hyde; P J Gotwals; V E Koteliansky; S T Ryan; S N Giri
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

3.  Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice.

Authors:  T Wyss-Coray; C Lin; D A Sanan; L Mucke; E Masliah
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

4.  Extraction and purification of TGFbeta and its effect on the induction of apoptosis of hepatocytes.

Authors:  X H Si; L J Yang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

5.  A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis.

Authors:  R Hernández-Pando; H Orozco-Esteves; H A Maldonado; D Aguilar-León; M M Vilchis-Landeros; D A Mata-Espinosa; V Mendoza; F López-Casillas
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

6.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis.

Authors:  Q Yu; I Stamenkovic
Journal:  Genes Dev       Date:  2000-01-15       Impact factor: 11.361

Review 7.  Clinical implications of matrix metalloproteinases.

Authors:  Malay Mandal; Amritlal Mandal; Sudip Das; Tapati Chakraborti; Chakraborti Sajal
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

8.  Latent TGF-β binding protein 4 promotes elastic fiber assembly by interacting with fibulin-5.

Authors:  Kazuo Noda; Branka Dabovic; Kyoko Takagi; Tadashi Inoue; Masahito Horiguchi; Maretoshi Hirai; Yusuke Fujikawa; Tomoya O Akama; Kenji Kusumoto; Lior Zilberberg; Lynn Y Sakai; Katri Koli; Motoko Naitoh; Harald von Melchner; Shigehiko Suzuki; Daniel B Rifkin; Tomoyuki Nakamura
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

9.  Mesangial cell apoptosis: the major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis.

Authors:  A J Baker; A Mooney; J Hughes; D Lombardi; R J Johnson; J Savill
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

10.  Aminoguanidine reduces glomerular inducible nitric oxide synthase (iNOS) and transforming growth factor-beta 1 (TGF-beta1) mRNA expression and diminishes glomerulosclerosis in NZB/W F1 mice.

Authors:  C W Yang; C C Yu; Y C Ko; C C Huang
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.